[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kang Stem Biotech Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":13,"conditions":21,"keywords":23,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100651032","a-multicenter-open-label-single-arm-extension-study-to-evaluate-the-safety-and-efficacy-of-furestem-oa-kit-inj-in-knee-osteoarthritis-patients-who-received-placebo-in-the-k0701-phase-2a-trial-100651032",false,"NCT07754175","A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial","Inclusion Criteria:\n\n* Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study\n* Participants who voluntarily provide written informed consent to participate in this extension study\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria:\n\n* Participants whom the investigator considers unsuitable for participation in this extension study.\n* Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study","ALL","19 Years",{"count":18,"type":19},36,"ESTIMATED","OBSERVATIONAL",[22],"Knee Osteoarthritis",[24,25],"FURESTEM-OA Kit Inj.","Knee Osteoarthritis Stem cell","RECRUITING","2026-08-04",{"date":29,"type":30},"2026-08-10","ACTUAL",{"date":32,"type":30},"2026-07-20",{"date":34,"type":19},"2032-02-28",{"name":36,"class":37},"Kang Stem Biotech Co., Ltd.","INDUSTRY",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":4},"100517112","long-term-follow-up-study-of-subjects-with-knee-osteoarthritis-who-had-administered-furestem-oa-kit-inj-in-k0701-study-100517112","NCT06013306","Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study","Inclusion Criteria:\n\n* Those who participated in the K0701 clinical trial and received PureStem-OA Kit Inj\n* Those who understand and voluntarily sign an informed consent form\n\nexclusion criteria\n\n* None",{"count":46,"type":19},58,"Long-Term Follow-up Study of Subjects with Knee Osteoarthritis who had administered FURESTEM-OA Kit Inj. in K0701 study",[22],"NOT_YET_RECRUITING","2023-08-28",{"date":52,"type":30},"2023-08-30",{"date":54,"type":19},"2023-09-14",{"date":56,"type":19},"2030-12-30",{"name":36,"class":37},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100418539","long-term-follow-up-study-to-evaluate-the-safety-and-explore-the-efficacy-of-multiple-doses-of-furestem-ad-inj-100418539","NCT04730024","Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj","Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results From the K0104 Extension Study","Inclusion Criteria:\n\n1. Subject who enrolled K0104 Clinical Trial(parent study).\n2. Subjects who understand and voluntarily sign an informed consent form\n\nExclusion Criteria:\n\n1. Subjects who are expected to be unable to perform at least one follow-up during this study (K0104-E)\n2. Subjects who has received\u002Fadministered clinical trial drugs or medical devices by participating in other clinical trials until the first visit of this trial (K0104-E) after the completion of K0104 clinical trial\n3. Subjects who are judged to be unsuitable for other researchers to participate in the research",{"count":66,"type":19},102,"A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study",[69],"Atopic Dermatitis","2021-01-25",{"date":72,"type":30},"2021-01-29",{"date":74,"type":19},"2022-03-27",{"date":76,"type":19},"2030-06-30",{"name":36,"class":37},1,""]